amprenavir has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Bao, J; Chen, J; Huang, G; Jiang, W; Li, C; Li, T; Li, X; Qi, P; Shi, W; Wang, H; Wang, Y | 1 |
1 review(s) available for amprenavir and Breast Neoplasms
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for amprenavir and Breast Neoplasms
| Article | Year |
|---|---|
Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis inducer in MCF-7 human breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Breast Neoplasms; Carbamates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Repositioning; Female; Furans; HIV Protease Inhibitors; Humans; Male; MCF-7 Cells; Mice; Mice, Inbred C57BL; Mice, Nude; Mitogen-Activated Protein Kinase 1; Molecular Docking Simulation; Molecular Dynamics Simulation; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2017 |